Industry Awaits US Appeal Ruling On Sandoz’ Enbrel Biosimilar

Sandoz’ Erelzi Version Held Up By IP Barriers

 
• By Dean Rudge
  
Gavel
Sandoz failed with invalidity attacks to two US patents in August last year • Source: Shutterstock

More from Biosimilars

More from Products